- The FDA approves AstraZeneca's (AZN -0.9%) Lynparza (olaparib) for the treatment of women with advanced ovarian cancer associated with defective BRCA genes. It was approved in Europe yesterday.
- Previously: AstraZeneca cancer drug cleared in Europe (Dec. 18, 2014)
FDA clears Lynparza for ovarian cancer
Recommended For You
More Trending News
About AZN Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| AZN | - | - |
| AstraZeneca PLC | ||